Format

Send to

Choose Destination
See comment in PubMed Commons below
Future Oncol. 2011 Jan;7(1):15-24. doi: 10.2217/fon.10.168.

Cabazitaxel for the treatment of castration-resistant prostate cancer.

Author information

1
University of Utah, Salt Lake City, Utah, UT, USA.

Abstract

Treatment with docetaxel-based chemotherapy results in improved survival in patients with metastatic castration-resistant prostate cancer. However, all patients eventually develop progressive disease associated with poor outcomes. In this article, we discuss the available second-line therapeutic options following docetaxel, with a special focus on cabazitaxel, which is the first agent to yield extended survival as second-line therapy following docetaxel. Cabazitaxel, a novel semi-synthetic taxane, is effective even in docetaxel-resistant model systems. Recently, results of the Phase III TROPIC trial demonstrated improved survival with cabazitaxel plus prednisone compared with mitoxantrone and prednisone in patients with progressive metastatic castration-resistant prostate cancer, following prior docetaxel, which led to approval by the US FDA.

PMID:
21174534
DOI:
10.2217/fon.10.168
[Indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Atypon
    Loading ...
    Support Center